Protara Therapeutics, Inc. Common Stock
TARAProtara Therapeutics, Inc. (TARA) is a biotechnology company focused on developing innovative therapies for cancer and rare diseases. It is dedicated to advancing treatments through its pipeline of novel drug candidates, with an emphasis on targeted and personalized medicine approaches.
Company News
Protara Therapeutics reported positive 12-month efficacy and safety data from its Phase 2 ADVANCED-2 trial of TARA-002 in BCG-naïve non-muscle invasive bladder cancer patients, demonstrating a 55% complete response rate at 12 months with no Grade 3 or greater adverse events. The company plans to initiate the registrational ADVANCED-3 trial in th...
Protara Therapeutics reported Q4 2025 results with a net loss of $17.3 million ($0.37 per share) and full-year loss of $57.4 million ($1.34 per share). The company announced interim data from its ADVANCED-2 trial showing TARA-002 achieved a 68% complete response rate at six months in BCG-Unresponsive bladder cancer patients with a favorable safet...
Protara Therapeutics announced participation in two upcoming investor conferences in February and March 2026, where management will hold fireside chats. The company also plans to present updated interim data from its Phase 2 ADVANCED-2 trial of TARA-002 for BCG-unresponsive non-muscle invasive bladder cancer patients at the ASCO Genitourinary Can...
Protara Therapeutics plans to raise approximately $75 million through a public offering of 13,043,479 common stock shares at $5.75 per share, with proceeds intended to fund clinical development of TARA-002 and other programs.
Protara Therapeutics plans to raise $75 million through a public offering of common stock and pre-funded warrants. The proceeds will fund clinical development of TARA-002 and other clinical programs, with J.P. Morgan, TD Cowen, and Piper Sandler acting as joint book-running managers.
